Form 4: Iovance Biotherapeutics Executive Vogt Reports Stock Transactions
SEC Form 4 Filing
Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On July 15, 2024, Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, had 20,835 restricted stock units (RSUs) vest.
- The company withheld 8,851 shares to satisfy tax withholding requirements at a price of $8.68 per share.
- Following these transactions, Vogt directly owns 159,309 shares of common stock and 41,669 RSUs.
- The remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation and stock ownership, with no inherent positive or negative implications for the company's overall prospects.
Future Outlook
The remaining RSUs will vest in equal quarterly installments.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| January 14, 2022 | Date of grant for the reported RSUs. |
| 07/15/2024 | Date of RSU vesting and tax withholding. |
| 07/17/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.